hemangiol
pierre fabre medicament - propranololihydrokloridia - hemangioma - beeta-estäjät - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.
labazenit
laboratoires smb s.a. - budesonide, salmeterol - astma - treatment of asthma.
montelukast navamedic 10 mg tabletti
navamedic asa - montelukastum natricum - tabletti - 10 mg - montelukasti
fomeda easyhaler 12 mikrog/annos inhalaatiojauhe
orion corporation - formoterol fumarate dihydrate - inhalaatiojauhe - 12 mikrog/annos - formoteroli
esketamine orifarm 5 mg/ml injektio-/infuusioneste, liuos
orifarm generics a/s - esketamine hydrochloride - injektio-/infuusioneste, liuos - 5 mg/ml - esketamiini
esketamine orifarm 25 mg/ml injektio-/infuusioneste, liuos
orifarm generics a/s - esketamine hydrochloride - injektio-/infuusioneste, liuos - 25 mg/ml - esketamiini
symbicort turbuhaler inhalaatiojauhe
astrazeneca oy - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - formoteroli ja budesonidi
astecon 10 mg tabletti, kalvopäällysteinen
avansor pharma oy avansor pharma oy - montelukastum natricum - tabletti, kalvopäällysteinen - 10 mg - montelukasti
astecon 4 mg purutabletti
avansor pharma oy avansor pharma oy - montelukastum natricum - purutabletti - 4 mg - montelukasti
astecon 5 mg purutabletti
avansor pharma oy avansor pharma oy - montelukastum natricum - purutabletti - 5 mg - montelukasti